China Supplier 2-(3-Methoxyphenyl)ethylamine - Edaravone CAS 89-25-8 High Purity 1-Pheny-3-Methyl-5-Pyrazolone (PMP) – Ruifu

Supply with High Purity and Stable Quality
Name: Edaravone
Synonyms: 3-Methyl-1-phenyl-5-pyrazolone; MCI-186
CAS: 89-25-8
Edaravone is a potent new free radical scavenger used for the therapy of patients with acute brain infarction.
High Quality, Commercial Production

Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer’s requirement.

Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.

Edaravone(MCI-186) is a potent new free radical scavenger used for the therapy of patients with acute brain infarction. Edaravone is a radical scavenger and antioxidant which is able to protect against the effects of ischemia, probably by inhibiting the lipoxygenase system. Protects against MPTP-induced neurotoxicity. Inhibits autophagy.

Edaravone was marketed in Japan for improving neurologic recovery following acute brain infarction. Currently, several agents classified as neuroprotectants and acting by diverse mechanisms (inhibition of glutamate release, blockade of calcium channels, lazaroids) have been marketed for treating the outcomes of brain damage due to trauma, ischemia or cardiac arrest. Edavarone is the first antioxidant with free radical scavenging activity to be introduced for this pathology. This previously described molecule (in particular as norantipyrine, one of three metabolites of antipyrine in mammals) can be simply prepared by direct cyclization of phenylhydrazine with alkylacetoacetate. Edarevone is a lipophilic agent, readily accessible to brain tissue, that is capable of reducing edema in the brain following ischemia by blocking the arachidonic acid cascade triggering peroxidative neurodegeneration. Interestingly, this agent has been shown to quench active oxygen species in endothelial cell homogenate, as well as inhibiting in vitro lipid peroxidative disintegration of membranes, so making this compound effective during reperfusion following ischemic injury. As an additional indication, phase III trials started with edaravone for increasing the chance of recovery after subarachnoid hemorrhage.

Edaravone may be used: As a reagent for the detection of reducing carbohydrates by ESI/MALDI-MS. To improve the sensitivity of reducing mono- and oligo-saccharides for their subsequent determination using capillary zone electrophoresis. For the precolumn derivatization of the monosaccharide components of Salvia miltiorrhiza, liguspyragine hydrochloride, and glucose injection prior to their analysis by high performance liquid chromatography (HPLC).